STOCK TITAN

Aura Biosciences: ADAR1 reports 5.2% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

For Aura Biosciences, Inc. (AURA), ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger, report shared voting and dispositive power over 5,385,879 common shares, representing 5.2% of the class. The shares are directly owned by private investment funds managed by ADAR1; ADAR1 and Schneeberger may be deemed to beneficially own them indirectly. The percentage is based on 103,950,771 shares outstanding as of September 30, 2026.

Beneficially owned shares 5,385,879 shares Shared voting and dispositive power reported by ADAR1 Capital Management and Daniel Schneeberger
Percentage of class 5.2% Based on Aura Biosciences common shares outstanding as of September 30, 2026
Common shares outstanding 103,950,771 shares As of September 30, 2026
beneficially owned regulatory
"Shares may be deemed indirectly beneficially owned by ADAR1 Capital Management and Daniel Schneeberger"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power regulatory
"5,385,879 shares reported with shared voting power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"5,385,879 shares reported with shared dispositive power"
investment adviser regulatory
"ADAR1 Capital Management described as an investment adviser"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AURA shares do ADAR1 Capital Management and Daniel Schneeberger report?

ADAR1 Capital Management, LLC and Daniel Schneeberger report shared voting and dispositive power over 5,385,879 Aura Biosciences common shares, equal to 5.2% of the class. The percentage is based on 103,950,771 shares outstanding as of September 30, 2026.

Who directly owns the AURA shares reported by ADAR1 Capital Management?

Private investment funds managed by ADAR1 Capital Management directly own the shares. ADAR1 and its sole manager, Daniel Schneeberger, may be deemed to beneficially own them indirectly, and both report shared voting and dispositive power over the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





05153U107

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 5,385,879 shares of common stock, par value $0.00001 per share ("Common Stock"), of Aura Biosciences, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 103,950,771 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 9, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 5,385,879 shares of common stock, par value $0.00001 per share ("Common Stock"), of Aura Biosciences, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 103,950,771 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 9, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

Keep reading